Clinical significance of expression of serum miR-146b and inflammatory factors for children with bronchopulmonary dysplasia
Objective To explore the clinical value and significance of miR-146b and inflammatory factor expression levels in children with bronchopulmonary dysplasia(BPD).Methods A total of 62 premature infants admitted to the Department of Neonatology of the First Affiliated Hospital of Shaoyang University in 2022 were collected.According to the diagnostic criteria for BPD,they were divided into a BPD group and a non BPD group.Umbilical cord blood samples and blood samples at different time points after birth were collected to detect the expression levels of miR-146b interleukin-1β(IL-1β),tumor necrosis factor α(TNF-α),and interleukin-6(IL-6)in blood samples.Results The expression levels of serum miR-146b in the non BPD group were higher than that in the BPD group at all time points after birth,and the differences were statistically significant(all P<0.05).On the third day after birth,the expression levels of serum miR-146b in the BPD group decreased to the lowest level,maintaining low from the 14th to the 28th day after birth,while that in the non BPD group gradually fell to the bottom on the 3rd to the 7th day after birth,and remained relatively stable,higher at all time points was than that in the BPD group.Moreover,the expression levels of inflammatory cytokine IL-1β,TNF-α and IL-6 in the non BPD group were lower than in the BPD group.In the BPD group,the expression level of TNF-α reached the peak on the third day after birth,then decreased,but remained at a high level,the expression level of IL-1β in cord blood was extremely high and gradually decreased over time,and the expression level of IL-6 remained stable from the 3rd to the 14th day after birth,with a significant decrease on the 28th day,but was still higher than that in the non BPD group(all P<0.05).Conclusion As BPD develops,low expression levels of miR-146b may promote the inflammatory development of BPD,but high expression levels of miR-146b may hinder this process and provide potential targets for the treatment of BPD.